It is a remarkable statement - the rock musician and drugs activist credited with spawning the global legal highs industry is now calling for new laws in Britain to protect the millions of young people who take the substances.
Legal highs are synthetic chemical substitutes for illegal recreational drugs such as cannabis, cocaine and ecstasy which often sell at a lower price. The industry has grown dramatically in the past decade in response to demand from clubbers and festival goers, but it has proved difficult to regulate, and some products have proved lethal.
Matt Bowden, 42, is known as the godfather of the legal highs industry. He was a user of crystal meth – a highly addictive form of amphetamine – in the 1990s until he teamed up with a pharmacologist in New Zealand to find a safer, synthetic alternative. Two family members had died from the effects of drugs and he concluded better substitutes must be developed.
The resulting product, called BZP, sold so well that it was noticed beyond New Zealand's borders. Soon budding chemists everywhere were busy tweaking the molecular structure of existing drugs such as cocaine and cannabis and selling them as "legal" alternatives for large amounts of money.
Dealers found that instead of negotiating an illegal supply of cocaine from dangerous south American thugs they could buy a kilo of mephedrone from a nice man from China with no questions asked.
Now Mr Bowden says that new regulations are needed to protect consumers from the products he helped spawn.
"The goal should be to encourage development of progressively safer alternatives to alcohol and the other drugs," he said, as figures were released showing an explosion in the number of new chemical substances coming on the market and in the number of online shops selling them.
The number of new chemical entities is growing each year and has increased threefold since 2008. Figures from the European drugs monitoring centre in Lisbon show 49 new substances were identified in 2011 up from 24 in 2009 and 13 in 2008.
There has also been a boom in online shops selling legal highs, up fourfold in the UK since 2010. Similar increases have been seen across Europe.
Mr Bowden, speaking from Paris where he is on holiday, said the legal high industry should be regulated like the drink, food or medicine industries. He had "stepped back" from running his company Stargate and now acts as a consultant on the industry to the New Zealand government.
"It is clearly possible to regulate. The level of regulation should be commensurate with the level of risk, and the majority of these drugs carry a level of risk far lower than the risks associated with many other normal daily activities including driving a car, swimming off the beach and drinking alcohol.
"However, given the political pressure on the consumption of drugs (other than alcohol) and the availability of technology and screening systems for risk analysis of new drugs developed for the pharmaceutical industry, it seems prudent that parallel systems be implemented for regulation of new psychoactives."
At a briefing in London this week organised by the Science Media Centre experts warned the growth of the industry posed an increasing risk.
Dr John Ramsey, a toxicologist from St George's Medical School, University of London, said: "There are 50 new compounds emerging each year. There were 49 in 2011 and 29 so far this year. What can we do about it? It is clearly not right that young people should be able to buy and use recreational drugs that have never been tested."
Dr Ramsey said it was "always possible" something would be produced that was "really toxic". A drug called MPTP caused symptoms of Parkinson's disease – tremor and stiffness – in every user who took it.
"We haven't had a drug that causes that level of harm since. Drug-related deaths usually involve more than one drug – it is impossible to say which caused it. In very few cases can we say this drug caused this death. But the potential is there for long-term chronic harm."
The appeal of legal highs is based on their price, availability and effectiveness. When supply problems with cocaine, a class A drug attracting the maximum penalty for possession, led to a drop in the purity of the drug available on the street and a rise in price, dealers stepped in, offering mephedrone which was cheaper, purer, Class B and had much the same effect.
In April, the Government banned methoxetamine, also known as Mexxy, under a temporary class drugs order, the first time the new power has been used, giving the Advisory Council of the Misuse of Drugs 12 months to assess its harms. But the effect of removing it from the market has been to make the advisory council's job in assessing it more difficult because there is less user experience to go on.
Dr Ramsey said: "Controlling this market by restricting supply is pretty much doomed to failure. The only way is to reduce demand. We need to persuade young people taking these drugs is a stupid thing to do."